A

mid ongoing criticism that some states continue to curb access to hepatitis C drugs, Colorado officials have lifted restrictions that determined when patients could receive treatment. Going forward, Medicaid beneficiaries will no longer have to demonstrate an advanced stage of liver disease to be treated.

In explaining their decision, state officials pointed to declining costs for the medicines, which have dropped in price recently as more new drugs become available. Over the summer, AbbVie (ABBV) introduced a treatment that costs $26,400, before rebates and discounts, for an eight-week regimen, which is significantly less than the $84,000 that Gilead Sciences (GILD) charged for 12 weeks of treatment for Sovaldi when it was first marketed four years ago.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.